| 1. |
|
|
| 2. |
|
|
| 3. |
- Filipsson, H. L., et al.
(author)
-
Seasonal variability of stable carbon isotopes (delta C-13(DIC)) in the Skagerrak and the Baltic Sea: Distinguishing between mixing and biological productivity
- 2017
-
In: Palaeogeography Palaeoclimatology Palaeoecology. - : Elsevier BV. - 0031-0182. ; 483, s. 15-30
-
Journal article (peer-reviewed)abstract
- We documented the annual cycle of the carbon isotopic composition of dissolved inorganic carbon (delta C-13(DIC)) in the water columns of the Skagerrak and Baltic Sea to obtain an increased understanding of the processes involved controlling the carbon isotopic distribution in shelf seas. The lowest delta C-13(DIC) values (-4.9%.) were found in the low -oxygen, brackish Baltic bottom water whereas the highest values (+1.8%0 were observed in the surface water of the Skagerrak during late summer. Photosynthesis drove the high delta C-13(DIC) values (between 1.0 and 1.8%.) noted in the surface waters of both the Skagerrak and the Baltic. The delta C-13(DIC) values below the halocline in the Baltic reflect mixing of brackish water and the more saline water from the Skagerrak, and foremost organic matter remineralization processes that release significant amounts of low delta C-13 CO2. Similarly, in the stagnant fjord basins, little deep water exchange and the degradation of terrestrial and marine organic matter set the delta C-13 composition. Deep-water renewal in the fjord basins resulted in rapid increases of the delta C-13(DIC) on the order of 1 6., whereas remineralization processes caused a decrease in delta C-13(DIC) of 0.1-03%0 per month depending on location. The combined effects of water mixing and remineralization processes (estimated using apparent oxygen utilization (AOU) values) yielded the expression: delta C-13(DIC=) 0.032 * S = 0.01 * AOU = 0.12 for the Baltic Skagerrak region at water depths below the halocline. (C) 2016 Elsevier B.V. All rights reserved.
|
|
| 4. |
- Greco, Raffaella, et al.
(author)
-
Innovative cellular therapies for autoimmune diseases : expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
- 2024
-
In: eClinicalMedicine. - : Elsevier. - 2589-5370. ; 69
-
Journal article (peer-reviewed)abstract
- Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications. Expert -based consensus and recommendations for best practice and quality of patient care were developed to support clinicians, scientists, and their multidisciplinary teams, as well as patients and care providers and will be regularly updated. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
|
|
| 5. |
|
|
| 6. |
- Schramm, W., et al.
(author)
-
Haemophilia Care in Europe: the ESCHQoL study
- 2012
-
In: Haemophilia. - : Wiley. - 1351-8216. ; 18:5, s. 729-737
-
Journal article (peer-reviewed)abstract
- The aim of this study was to determine the clinical conditions of patients with haemophilia within Europe as recommended by the European Commission. In this multicentre, cross-sectional, ambispective study, conducted within 21 European countries patients' clinical data were collected, amongst others haemophilia type, severity, treatment pattern, use of factor products, bleeding, orthopaedic joint scores and infections. A total of 1400 patients, 84.3% with haemophilia A and 15.7% with haemophilia B were enrolled by 42 centres between 2004 and 2006. Thereof, 417 were children (30.0%) and 983 were adults (70.0%). About 70% of patients had severe factor deficiency (<1%). More than half of the adults were carriers of chronic infections (12.6% HIV, 55.8% HCV), compared to only 3.8% children (no HIV, 2.9% HCV). Patients were grouped according to per capita amount of clotting factor used in patients' region of residence in 2005: region 1: >5 IU; region 2: 25 IU; region 3: <2 IU. Paediatric and adult patients in region 3 had median numbers of three and eight joint bleeds, respectively, with worse joint scores compared to region 1 with zero and one bleed. Prophylactic therapy was used in only 31.3% children and 8.9% adults with severe haemophilia in region 3 compared to 93.7% and 54.1%, respectively, in region 1. Statistical analysis revealed that residence in areas with low factor consumption/availability is the most prominent risk factor for joint disease. Access of European patients with haemophilia to optimal care with safe factor VIII concentrates is limited and depends on the region of residence.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Gringeri, A, et al.
(author)
-
A Randomized Clinical Trial of Prophylaxis in Children with Hemophilia A (the ESPRIT Study).
- 2011
-
In: Journal of Thrombosis and Haemostasis. - : Elsevier BV. - 1538-7933 .- 1538-7836. ; 9, s. 700-710
-
Journal article (peer-reviewed)abstract
- Background: Prevention of arthropathy is a major goal of hemophilia treatment. While studies in adults have demonstrated an impact of prophylaxis on the incidence of joint bleeds and patients' well-being in terms of improved quality of life (QoL), it is unclear whether or not prophylaxis influences the outcome and well-being perception of children with hemophilia. Objective: This randomized controlled study compared the efficacy of prophylaxis with episodic therapy in preventing hemarthroses and image-proven joint damage in children with severe hemophilia A (factor VIII <1%) over a 10-year time period. Methods: Forty-five children with severe hemophilia A, aged 1-7 years (median 4), with negative clinical-radiological joint score at entry and at least one bleed during the previous 6 months, were consecutively randomized to prophylaxis with recombinant factor VIII (25 IU/Kg 3x week) or episodic therapy with ≥25 IU/Kg every 12-24 hours until complete clinical bleeding resolution. Safety, feasibility, direct costs and QoL were also evaluated. Results: Twenty-one children were assigned to prophylaxis, 19 to episodic treatment. Children on prophylaxis had fewer hemarthroses than children on episodic therapy: 0.20 vs. 0.52 events/patient/month (p<0.02). Plain-film radiology showed signs of arthropathy in 6 patients on prophylaxis (29%) vs. 14 on episodic treatment (74%) (p<0.05). Prophylaxis was more effective when started early (≤36 months) with patients having less joint bleeds (0.12 joint bleeds/patient/month) and no radiologic signs of arthropathy. Conclusion: This randomized trial confirms the efficacy of prophylaxis in preventing bleeds and arthropathy in children with hemophilia, particularly when it is initiated early in life.
|
|
| 10. |
|
|
